Back to dashboard
All PlansCoverageMedium impact

Maternal Serum Biomarkers for Prediction of Adverse Obstetric Outcomes

Blue Cross & Blue Shield of Mississippi·MS · OB-GYN, Family Medicine, Internal Medicine·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

This new medical policy establishes coverage criteria for maternal serum biomarker testing to predict preeclampsia and spontaneous preterm birth in pregnant women. The policy covers FDA-cleared tests like B·R·A·H·M·S sFlt-1/PlGF for hospitalized women with hypertensive disorders and laboratory-developed tests for risk assessment.

Action Required

Action needed
Immediately: Review new Policy A.2.04.152 for maternal serum biomarker testing coverage criteria. Update prior authorization protocols for biomarker tests in pregnant women aged 18+ between 23-34 weeks gestation with hypertensive disorders. Train staff on documentation requirements for preeclampsia and preterm birth risk assessment testing.

Related policy hubs